Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have received a consensus rating of "Moderate Buy" from the eight ratings firms that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $21.14.

Several research analysts recently commented on YMAB shares. Wedbush restated an "outperform" rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a report on Tuesday, September 10th. BMO Capital Markets cut their price target on shares of Y-mAbs Therapeutics from $26.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 13th. HC Wainwright reiterated a "buy" rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set an "underweight" rating for the company in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group reiterated a "buy" rating and issued a $26.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, August 13th.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In other news, insider Thomas Gad sold 30,000 shares of the firm's stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the completion of the sale, the insider now owns 67,681 shares in the company, valued at approximately $877,822.57. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Joris Wilms sold 5,000 shares of the firm's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $14.69, for a total transaction of $73,450.00. Following the transaction, the chief operating officer now directly owns 30,600 shares in the company, valued at approximately $449,514. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,000 shares of company stock worth $1,338,100. 21.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Y-mAbs Therapeutics

A number of hedge funds have recently bought and sold shares of YMAB. Squarepoint Ops LLC increased its position in Y-mAbs Therapeutics by 143.4% during the second quarter. Squarepoint Ops LLC now owns 126,389 shares of the company's stock worth $1,527,000 after acquiring an additional 74,452 shares during the period. Millennium Management LLC increased its holdings in Y-mAbs Therapeutics by 23.8% in the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company's stock valued at $4,225,000 after buying an additional 67,233 shares during the period. Dimensional Fund Advisors LP increased its holdings in Y-mAbs Therapeutics by 15.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company's stock valued at $5,853,000 after buying an additional 65,732 shares during the period. Boston Partners bought a new position in Y-mAbs Therapeutics in the 1st quarter valued at about $556,000. Finally, XTX Topco Ltd bought a new position in Y-mAbs Therapeutics in the 2nd quarter valued at about $297,000. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Stock Down 1.1 %

YMAB traded down $0.16 during trading hours on Friday, hitting $14.48. 198,956 shares of the company's stock were exchanged, compared to its average volume of 334,405. Y-mAbs Therapeutics has a 1-year low of $4.69 and a 1-year high of $20.90. The stock's 50-day moving average is $13.92 and its two-hundred day moving average is $13.14. The stock has a market cap of $635.43 million, a price-to-earnings ratio of -29.55 and a beta of 0.70.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.08). Y-mAbs Therapeutics had a negative return on equity of 24.88% and a negative net margin of 28.44%. The business had revenue of $22.80 million for the quarter, compared to analyst estimates of $23.09 million. During the same quarter in the previous year, the company posted ($0.14) EPS. On average, equities research analysts anticipate that Y-mAbs Therapeutics will post -0.6 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.